NOVARTIS AG CEDEAR EACH REP 0.5 (NVS.BA)


Buenos Aires - Buenos Aires Delayed Price. Currency in ARS
585.000.00 (0.00%)
At close: 10:20 AM EDT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open585.00
Prev Close585.00
Bid585.00 x
Ask585.00 x
Day's Range585.00 - 585.00
52wk Range585.00 - 605.50
1y Target EstN/A
Market CapN/A
P/E Ratio (ttm)N/A
BetaN/A
Volume20
Avg Vol (3m)32
Dividend & YieldN/A (N/A)
Earnings DateN/A
  • Novartis (NVS) Zykadia Positive in Phase III ASCEND-4 Study
    Zacks2 days ago

    Novartis (NVS) Zykadia Positive in Phase III ASCEND-4 Study

    Novartis (NVS) announced positive top-line data from the phase III ASCEND-4 study on Zykadia to treat patients with ALK+ NSCLC.

  • Reuters2 days ago

    UPDATE 1-Novartis's Zykadia gets positive results, faces Roche pressure

    Novartis's Zykadia drug performed well against a rare form of lung cancer, the Swiss company said on Friday, citing a study it hopes will help it win expanded regulatory approval for the use of the drug. Novartis released results of a phase III clinical trial of Zykadia, or ceritinib, on previously untreated patients with advanced anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer. Patients treated with Zykadia showed a significant improvement in their chances of surviving without the cancer spreading compared with standard chemotherapy, the firm said.

  • Does Novartis AG (NVS) Have The Solution For Malaria?
    Insider Monkey3 days ago

    Does Novartis AG (NVS) Have The Solution For Malaria?

    Results for a potentially game-changing proof of concept study were just published concerning malaria by Novartis AG (NYSE:NVS) in the New England Journal of Medicine. The results show that KAF156, a new antimalarial compound, has demonstrated activity in opposition to both falciparum and vivax malaria and artemisinin-resistant parasites. Malaria, A Life Threatening Disease Malaria is a mosquito-borne life-threatening […]